Privi Speciality Chemicals Ltd Q4 FY2026 Concall Summary

Key Takeaways

• 22% revenue growth, volume-led: FY26 revenue grew 22% on 6.5% volume growth, ~8% price increase and improved mix, with sustained demand across key end-user industries.
• EBITDA margin jumped 341 bps to 25.76%: Operational efficiencies, cost optimization, better capacity utilization and lower admin expenses drove the expansion; management sees ~25% as sustainable.
• PRIGIV turned profitable in Q4: The Givaudan JV delivered its first profitable quarter, and consolidated margins are expected to improve from here.
• Capex Phase 1 on track for June 2026 completion: Total installed capacity will rise to 54,000 metric tons, with ethyl maltol, maltol and cyclopentanone targeting mechanical completion by end-Q1 FY27.
• What to watch next quarter: Commercial production start for the three new molecules, NCLT merger filing progress, and whether the Q4 gross margin dip reverses as the annual raw-material contract overlap unwinds.

Financial Performance

• Revenue engine: FY26 revenue growth of 22% was driven by volume growth (6.5%), price increase (~8%) and improved product mix, supported by sustained demand across key end-user industries and increasing traction in speciality and value-added product segments.
• Realization trajectory: Realization has steadily climbed from ~₹450/kg to ~₹525/kg to ~₹600/kg over the last 5 years. Future growth will be calibrated as the product mix includes both high-value molecules and lower-priced products like cyclopentanone.
• EBITDA margin walk: EBITDA margin improved to 25.76% in FY26 from 22.35% in FY25, driven by stable input costs, operational efficiencies, cost optimization, improved capacity utilization, and reduction in manufacturing and other administrative expenses.
• Q4 gross margin dip: A sequential dip in gross margin occurred in Q4 due to the overlap of raw material annual contracts with the first calendar quarter. Management says this is a recurring historical pattern and advises judging on an annualized basis.
• Power and fuel cost control: Power and other expenses declined both sequentially and YoY despite strong revenue growth and West Asia disruption, credited to the engineering team's ProMax program for saving steam and power and utilizing residual steam, plus tight cost control and precise freight contract negotiation.
• Forex calibration: Rupee depreciation provides some benefit but is calibrated because 70% of raw materials are imported and the company carries forex debt.
• Working capital discipline: The working capital cycle reduced to 117 days in FY26 due to excellent management and constant monitoring. Even if working capital increases due to the current situation, it will not be more than 3-5%.
• State incentives: Expected to remain in a similar range (~₹13 crore), based on 50% of GST on local state sales.

Babani: "We always want to see a happy customer. A smile on his face keeps our day and keeps our balance sheet very alive."

Capex & Capacity Expansion

• Phase 1 on track: The first phase of capex expansion is on track to complete by June 30, 2026, taking total installed capacity to 54,000 metric tons per annum, with additional capacities to be commissioned progressively over coming quarters.
• Phase 2 progressing: Phase 2 of the multi-speciality aroma chemicals project is progressing as planned.
• Three new molecules timeline: Ethyl maltol, maltol and cyclopentanone projects are targeting mechanical completion by end of Q1 FY27 (June 2026), with commercial production approximately one month after trials.
• All three phases completion: Optimistically June 2028, more realistically September 2028.
• Furfural backward integration: The company will first establish finished goods, then pursue backward integration, with a timeline of approximately two years from now, around FY28-29.
• Plant operations healthy: Plant utilizations remained healthy across major product lines, and operational excellence initiatives (process optimization, yield improvement, energy efficiency, debottlenecking) improved throughput while maintaining cost discipline.

PRIGIV & Consolidated Outlook

• PRIGIV turned profitable: The Givaudan JV delivered its first profitable quarter in Q4 FY26.
• Revenue ramp: PRIGIV is expected to generate ~₹130 crore in sales in FY27, up from ~₹55 crore in FY26, with a target of at least ₹300 crore revenue in the next 3-4 years at decent margins.
• Additional capex: An additional ₹50 crore of capex is being implemented based on equity infusion by Privi and Givaudan in a 51:49 ratio.
• Consolidated margin uplift: Consolidated margins are expected to improve now that PRIGIV is turning positive.
• JV structure confirmed: Management confirmed only one JV exists with Givaudan, for manufacturing certain high-end specialty chemicals exclusively for Givaudan SA; the other entity is a 100% subsidiary.

New Products & Biotech

• Specialty molecules pipeline: Silver Amber, Amber Silk, Privilege and Privitolide: one has already been commissioned, and the others will be commissioned during FY27. Revenues from new specialty molecules are expected in the next 18 months onwards.
• Margins on new products confidential: Management declined to share margin expectations for the new molecules, citing the need to maintain confidentiality.
• Biotech demonstration plant: A demonstration plant for biomass conversion (biowaste to value-added products) is being set up with capex of ₹70-75 crore. Basic engineering is underway, moving to detailed engineering, with the plant expected to come up in the next ~12 months.
• Biotech economics unproven: The purpose of the demonstration plant is to assess overall economics in detail. Management sees merits in the biotechnology route but has not identified specific molecules or crossover points where bio-waste routes achieve cost parity with petrochemical routes.
• Market strategy under development: The company is still assessing market elasticity for biotech-derived products, exploring scenarios like launching at \$45 and what demand response that would trigger.
• Scale-up timeline distant: Full-scale launch is 3-4 years away after market research, and the top team is working separately on the "beyond 5,000-ton" story.

Patil: "So the very purpose of putting a demonstration plant is to assess in detail the overall economics. And as we stand here today, we do see merits in biotechnology route and adding value to that."

Merger & Corporate Actions

• Merger progress: The company received an observation letter with no objection from BSE and NSE for the proposed merger of Privi Speciality Chemicals Ltd, Privi Fine Sciences Pvt Ltd and Privi Biotechnologies Pvt Ltd with the parent company. The filing with NCLT is next, with final approval expected during FY27, internally targeted for Q3 FY27.
• Dividend: The board recommended a dividend of ₹10 per share for FY26, a payout of 100% of face value.

Margin Sustainability & Pricing Power

• ~25% EBITDA margin seen as sustainable: Management stated EBITDA margin should remain at ~25% levels, noting "we are manufacturers of chemicals and not magicians" so there is a limit to margin expansion, but absolute EBITDA will grow with scale.
• Gross margin assumption: Management advised assuming gross margin remains at a similar level, with internal efficiency improvements continuing.
• Pricing power demonstrated: The company is confident of being able to pass on price increases to customers. Realization has steadily increased over five years, and management believes customers accept paying 1-2% higher because Privi is a better supplier.
• Customer discussions undisclosed: When asked about engagement with MNCs and spot customers during tough times, management declined to share details, citing that the call was being recorded.

Patil: "I'm not saying I'm the most competitive, but I am definitely in the league and people do have confidence by paying 1% or 2% higher, Privi is a better supplier."

Guidance & Commitments

Key Metrics